• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRI™ Website
      • ISPRI Downselect™
      • ISPRI Quantify™
      • ISPRI Analyze™
      • ISPRI Evaluate™
      • ISPRI-HCP™
      • ISPRI Design™
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAX™
      • EpiCC™
      • Ancer®
      • PreVAX™
    • Lab Services
      • All In Vitro Assays
      • Generic Peptide PANDA® Assays
    • Consulting Services
      • Trusted Expert Advice (TEA)
      • IRA / ISI Regulatory Writing Support
  • About Us
    • Leadership
    • Careers
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
Activation of natural regulatory T cells by IgG Fc–derived peptide “Tregitopes”

Activation of natural regulatory T cells by IgG Fc–derived peptide “Tregitopes”

by Sarah Moniz | Feb 6, 2018

Immuno-informatics: Mining the genome for Vaccine Components

Immuno-informatics: Mining the genome for Vaccine Components

by Adam | Oct 22, 2016

Immunology and Cell Biology. Immunology and Cell Biology (2002) 80, 255–269.
Analyzing Mycobacterium tuberculosis proteomes for candidate vaccine epitopes

Analyzing Mycobacterium tuberculosis proteomes for candidate vaccine epitopes

by Adam | Oct 22, 2016

Tuberculosis (Edinb). 2005; 85(1-2):95-105.
Developing an epitope-driven tuberculosis (TB) vaccine

Developing an epitope-driven tuberculosis (TB) vaccine

by Adam | Oct 22, 2016

Vaccine. 2005 Mar 18; 23(17-18):2121-31.
Confirmation of Immunogenic Consensus Sequence HIV-1 T-cell Epitopes in Bamako, Mali and Providence, Rhode Island

Confirmation of Immunogenic Consensus Sequence HIV-1 T-cell Epitopes in Bamako, Mali and Providence, Rhode Island

by Adam | Oct 22, 2016

Human Vaccines 2006 June; 2(3), 119-128.
« Older Entries

Recent Posts

  • EpiVax Enters its Next Chapter with SV Health Investors
  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy 
  • BEBPA Workshop: Streamlining Immunogenicity Assessment of Host Cell Proteins
  • Advancing Immunogenicity Science: EpiVax in 2025 
  • EpiVax Supports Life-Saving Programs Through Partnerships with GAIA Vaccine Foundation and Clínica Esperanza/Hope Clinic

Recent Comments

  1. Homepage on Doing Well and Giving Back in December

Join our newsletter

Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.